Physician profile
Arthur Manoli
NPI 1700271137
$24,794.43
in general payments reported to CMS, 2019-2025
12 companies · $1,226 in 2025
The $1,226 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16K · 2021: $62.71 · 2022: $1,318 · 2023: $267 · 2024: $5,504 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,553 · Travel and Lodging: $3,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,553.23 |
| Travel and Lodging | $3,443.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $16,374.87 | 2020 | |
| Ortho Development Corporation | $4,605.22 | 2024-2025 | |
| Stryker Corporation | $1,341.62 | 2022-2024 | Mako |
| Maxx Orthopedics, INC. | $1,195.30 | 2023-2024 | |
| Uoc USA INC | $491.90 | 2024-2025 | U2 and Ustar II, U2, Conformity, U-Motion II, U-Star, U2 Pf+ |
| Zimmer Biomet Holdings, INC. | $161.14 | 2021-2024 | Persona |
| Medical Device Business Services, INC. | $149.30 | 2020-2025 | Reclaim |
| Paragon 28, INC. | $147.79 | 2023 | Apex 3d |
| Orthalign INC | $143.40 | 2024-2025 | Orthalign Plus |
| Kinamed, INC. | $64.97 | 2024 | |
| Kerecis Limited | $62.36 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Depuy Synthes Sales INC. | $56.56 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Manoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.